Painreform Ltd (PRFX)

$0.83 +0.02 (2.63%)
Market Cap 1.63M
Revenue (ttm) 0.00
Net Income (ttm) -14.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 120,600
Avg Vol 375,914
Day's Range N/A - N/A
Shares Out 2.01M
Stochastic %K 63%
Beta 0.59
Analysts Strong Buy
Price Target $47.99

Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operatio...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 7177050
Address:
65 Yigal Alon St., Tel Aviv, Israel
Weimanator
Weimanator Jan. 15 at 3:16 PM
$PRFX
0 · Reply
Aburose
Aburose Jan. 13 at 9:51 PM
$PRFX no body likes this sector they use positive announcement to sell on you
0 · Reply
Aburose
Aburose Jan. 13 at 9:42 PM
$PRFX PainReform And LayerBio Announce Safety Data Supporting Continued Development Of OcuRing-K Drop-Less, Sustained-Release Ocular Drug Delivery Platform For Use In Cataract Surgery. deserves 10-12
0 · Reply
Aburose
Aburose Jan. 13 at 9:41 PM
$PRFX trash as other has great news but no money to takeoff
0 · Reply
Aburose
Aburose Jan. 13 at 9:36 PM
$PRFX 2-3 great news
0 · Reply
SqueezeMagnet33
SqueezeMagnet33 Jan. 13 at 6:00 PM
$PRFX back to undervalued .. Dip Buyers . ✅
0 · Reply
100K2022
100K2022 Jan. 13 at 2:43 PM
$PRFX volume sucks
0 · Reply
Ashamo
Ashamo Jan. 13 at 2:17 PM
$PRFX any moves here today?
0 · Reply
Pandy1
Pandy1 Jan. 13 at 11:11 AM
$PRFX likes it .80 mark a lot ! Guess accumulation for the compliance run
0 · Reply
First_Class_Seaman
First_Class_Seaman Jan. 13 at 12:27 AM
$PRFX I messaged a lot of you about the news today, and we got it
0 · Reply
Latest News on PRFX
PainReform's LayerBio's Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies

Jan 12, 2026, 9:00 AM EST - 3 days ago

PainReform's LayerBio's Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies

PainReform's DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market

Jan 5, 2026, 9:00 AM EST - 10 days ago

PainReform's DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market

BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week

Dec 30, 2025, 8:48 AM EST - 16 days ago

BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week

PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities

Dec 10, 2025, 8:30 AM EST - 5 weeks ago

PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities

PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy

Dec 2, 2025, 9:15 AM EST - 6 weeks ago

PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy

PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis

Nov 12, 2025, 9:00 AM EST - 2 months ago

PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis

PainReform's DeepSolar, Developing “DeepSolar Predict” within the NVIDIA Connect Program, Featured in The Market Link's “Watchlist Interview” and Announces Progress Toward Pilot Projects

Nov 5, 2025, 8:30 AM EST - 2 months ago

PainReform's DeepSolar, Developing “DeepSolar Predict” within the NVIDIA Connect Program, Featured in The Market Link's “Watchlist Interview” and Announces Progress Toward Pilot Projects

PainReform Provides Business Update for the Six Months Ended June 30, 2025

Oct 1, 2025, 9:27 AM EDT - 3 months ago

PainReform Provides Business Update for the Six Months Ended June 30, 2025

PainReform/DeepSolar Accepted into NVIDIA Connect Program

Aug 19, 2025, 8:30 AM EDT - 5 months ago

PainReform/DeepSolar Accepted into NVIDIA Connect Program

PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System

Aug 13, 2025, 8:30 AM EDT - 5 months ago

PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System

PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio

Jul 10, 2025, 8:30 AM EDT - 6 months ago

PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio

Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

May 27, 2025, 12:12 PM EDT - 8 months ago

Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects

May 7, 2025, 4:30 PM EDT - 9 months ago

PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects

PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

Apr 10, 2025, 8:30 AM EDT - 10 months ago

PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

PainReform Provides Year-End Business Update

Apr 7, 2025, 5:00 PM EDT - 10 months ago

PainReform Provides Year-End Business Update

PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

Mar 5, 2025, 11:00 AM EST - 11 months ago

PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

Feb 18, 2025, 8:30 AM EST - 11 months ago

PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

Dec 27, 2024, 8:30 AM EST - 1 year ago

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

Nov 20, 2024, 8:30 AM EST - 1 year ago

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Nov 7, 2024, 5:00 PM EST - 1 year ago

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

Sep 11, 2024, 8:30 AM EDT - 1 year ago

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

Sep 10, 2024, 9:46 AM EDT - 1 year ago

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

Aug 20, 2024, 8:30 AM EDT - 1 year ago

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

Aug 7, 2024, 10:00 AM EDT - 1 year ago

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

Aug 1, 2024, 8:30 AM EDT - 1 year ago

PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

May 31, 2024, 4:15 PM EDT - 1 year ago

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

PainReform Provides Business Update for the First Quarter of 2024

May 15, 2024, 4:05 PM EDT - 1 year ago

PainReform Provides Business Update for the First Quarter of 2024

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

May 8, 2024, 8:30 AM EDT - 1 year ago

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

PainReform Announces Closing of $4 Million Public Offering

Apr 18, 2024, 2:19 PM EDT - 1 year ago

PainReform Announces Closing of $4 Million Public Offering

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

Apr 9, 2024, 9:00 AM EDT - 1 year ago

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

Apr 2, 2024, 8:30 AM EDT - 1 year ago

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

PainReform to Present at the Microcap Conference in Atlantic City

Jan 22, 2024, 8:30 AM EST - 2 years ago

PainReform to Present at the Microcap Conference in Atlantic City

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

Jan 3, 2024, 8:30 AM EST - 2 years ago

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

Dec 26, 2023, 6:00 PM EST - 2 years ago

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

PainReform Provides Business Update for the Third Quarter of 2023

Nov 15, 2023, 4:05 PM EST - 2 years ago

PainReform Provides Business Update for the Third Quarter of 2023

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

Sep 11, 2023, 8:30 AM EDT - 2 years ago

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

Sep 7, 2023, 10:00 AM EDT - 2 years ago

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

Sep 5, 2023, 8:30 AM EDT - 2 years ago

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

PainReform Provides Business Update for the Second Quarter of 2023

Aug 10, 2023, 4:05 PM EDT - 2 years ago

PainReform Provides Business Update for the Second Quarter of 2023

PainReform Regains Compliance with Nasdaq Continued Listing Requirements

Jul 19, 2023, 9:00 AM EDT - 2 years ago

PainReform Regains Compliance with Nasdaq Continued Listing Requirements

PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement

Jul 14, 2023, 2:35 PM EDT - 2 years ago

PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement

PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement

Jul 12, 2023, 9:05 AM EDT - 2 years ago

PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement

PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st

Jun 15, 2023, 8:30 AM EDT - 2 years ago

PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st

PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

Jun 7, 2023, 4:30 PM EDT - 2 years ago

PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

PainReform Provides Business Update for the First Quarter of 2023

May 15, 2023, 4:45 PM EDT - 2 years ago

PainReform Provides Business Update for the First Quarter of 2023

PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

May 1, 2023, 8:30 AM EDT - 2 years ago

PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery

Mar 28, 2023, 9:10 AM EDT - 3 years ago

PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

Mar 16, 2023, 8:00 AM EDT - 3 years ago

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Feb 7, 2023, 4:05 PM EST - 3 years ago

PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

PainReform Provides Business Update for the Third Quarter of 2022

Nov 15, 2022, 8:30 AM EST - 3 years ago

PainReform Provides Business Update for the Third Quarter of 2022

Weimanator
Weimanator Jan. 15 at 3:16 PM
$PRFX
0 · Reply
Aburose
Aburose Jan. 13 at 9:51 PM
$PRFX no body likes this sector they use positive announcement to sell on you
0 · Reply
Aburose
Aburose Jan. 13 at 9:42 PM
$PRFX PainReform And LayerBio Announce Safety Data Supporting Continued Development Of OcuRing-K Drop-Less, Sustained-Release Ocular Drug Delivery Platform For Use In Cataract Surgery. deserves 10-12
0 · Reply
Aburose
Aburose Jan. 13 at 9:41 PM
$PRFX trash as other has great news but no money to takeoff
0 · Reply
Aburose
Aburose Jan. 13 at 9:36 PM
$PRFX 2-3 great news
0 · Reply
SqueezeMagnet33
SqueezeMagnet33 Jan. 13 at 6:00 PM
$PRFX back to undervalued .. Dip Buyers . ✅
0 · Reply
100K2022
100K2022 Jan. 13 at 2:43 PM
$PRFX volume sucks
0 · Reply
Ashamo
Ashamo Jan. 13 at 2:17 PM
$PRFX any moves here today?
0 · Reply
Pandy1
Pandy1 Jan. 13 at 11:11 AM
$PRFX likes it .80 mark a lot ! Guess accumulation for the compliance run
0 · Reply
First_Class_Seaman
First_Class_Seaman Jan. 13 at 12:27 AM
$PRFX I messaged a lot of you about the news today, and we got it
0 · Reply
CaptainsLogs
CaptainsLogs Jan. 12 at 11:40 PM
$ATER $F $MTEN $MULN.X $PRFX let’s stomp them out
0 · Reply
thetruth149
thetruth149 Jan. 12 at 11:39 PM
$MTEN ... Bulls from 658 Watchers to 726..... Like I said before, we got work to do..... this stock is riddled with shorts...... $ATER $F $MULN.X $PRFX
0 · Reply
Tygalastkings187
Tygalastkings187 Jan. 12 at 8:43 PM
$PRFX news after news!!! Matter of time now 🧨🔥🚀
0 · Reply
SqueezeMagnet33
SqueezeMagnet33 Jan. 12 at 7:59 PM
$PRFX Dip Buyers . 👀 $EVTV Extraordinary %325🚀 $AKAN From $2.37 😇 $OSRH on watch . 👀
0 · Reply
Trader4life69
Trader4life69 Jan. 12 at 7:19 PM
$PRFX Added some today like i said i would.. Really wanting more . . add end of day?
0 · Reply
SqueezeMagnet33
SqueezeMagnet33 Jan. 12 at 2:22 PM
$PRFX Great news .
0 · Reply
SqueezeMagnet33
SqueezeMagnet33 Jan. 12 at 2:22 PM
$PRFX Added that dip . ✅
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 2:20 PM
$PRFX 09:09 on Jan. 12 2026 PainReform And LayerBio Announce Safety Data Supporting Continued Development Of OcuRing-K Drop-Less, Sustained-Release Ocular Drug Delivery Platform For Use In Cataract Surgery #tradeideas
0 · Reply
First_Class_Seaman
First_Class_Seaman Jan. 12 at 2:13 PM
$PRFX I'm in
1 · Reply
First_Class_Seaman
First_Class_Seaman Jan. 12 at 2:12 PM
$PRFX
0 · Reply
First_Class_Seaman
First_Class_Seaman Jan. 12 at 2:06 PM
$PRFX News
0 · Reply
Stock_Catcher
Stock_Catcher Jan. 12 at 2:00 PM
$PRFX PRFX PainReform’s LayerBio’s Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies
0 · Reply